.png){kind=logo}
Overview
Wacker Biotech is the expert CDMO for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span multiple modalities, including direct plasmid DNA, pDNA for viral vector delivery, and pDNA as the starting material, and pDNA as a starting material for mRNA, for which we encompass the full manufacturing value chain through the IVT of mRNA to lipid nanoparticle (LNP) formulation. We have the capability to produce at diverse scales up to 1500 L and recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization.
We operate five GMP manufacturing facilities in the US (San Diego), Germany (Halle and Jena) and The Netherlands (Amsterdam). Complementing our bioprocess development and manufacturing experts at these four sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry and biochemistry advances. We have 30+ years of experience developing biologics to advance human and animal health.
Company News
